1	Full title: A pragmatic pipeline for drug resistance identification in <i>Mycobacterium tuberculosis</i> using
2	whole genome sequencing
3	
4	Short title: A sequencing pipeline for diagnosing Mycobacterium tuberculosis
5	
6	Authors:
7	Linzy Elton ¹ , Alp Aydin ² , Neil Stoker ¹ , Sylvia Rofael ^{1,3} , Letícia Muraro Wildner ¹ , Jabar Babatunde
8	Pacome Agbo Achimi Abdul ⁴ , John Tembo ⁵ , Muzamil Abdel Hamid ⁶ , Mfoutou Mapanguy Claujens
9	Chastel ^{7,8} , Julio Ortiz Canseco ⁹ , Ronan Doyle ¹⁰ , Giovanni Satta ^{1,11} , Justin O'Grady ² , Adam Witney ¹² ,
10	Francine Ntoumi ^{7,8} , Alimuddin Zumla ^{1,13} , Timothy D McHugh ¹
11	
12	Institutional affiliations:
13	1. Centre for Clinical Microbiology, University College London, UK
14	2. Oxford Nanopore Technologies plc. Quadram Institute, Rosalind Franklin Road, Norwich
15	Research Park, Norwich, UK
16	3. Faculty of Pharmacy, Alexandria University, Egypt
17	4. Centre de Recherches Médicales de Lambaréné, Gabon
18	5. HerpeZ, University Teaching Hospital, Lusaka, Zambia
19	6. Institute for Endemic Diseases, University of Khartoum, Khartoum, Sudan
20	7. Fondation Congolaise pour la Recherche Médicale, Republic of Congo
21	8. Université Marien Ngouabi, Brazzaville Republic of Congo
22	9. Francis Crick Institute, London, UK
23	10. London School of Hygiene and Tropical Medicine, University of London, London, UK
24	11. University College London Hospitals NHS Foundation Trust, London, UK
25	12. St George's, University of London, London, UK

- 26 13. National Institute for Health Research Biomedical Research Centre, University College
- 27 London Hospitals NHS Foundation Trust, London, UK
- 29 Corresponding author: Dr Linzy Elton, Centre for Clinical Microbiology, University College London,
- 30 UK. Email: <u>linzy.elton@ucl.ac.uk</u> Tel: +44 (0)20 8016 8189

- 52 Word count:
- 53 Abstract: 215
- 54 Manuscript: 3501
- 55
- 56 Tables:
- 57 Table 1. Comparison of basecalling algorithms
- 58 Table 2. Concordance of different basecalling models, assuming greatest accuracy using SUP
- 59 basecalling
- Table 3. Summary comparison of the TB sequencing data analysis software Mykrobe, as compared
- 61 against TB-Profiler
- 62 Table 4. Table of pipeline steps and overall recommended choice for each section of the pipeline
- 63
- 64 Figures:
- Figure 1. Genomic DNA yield and integrity obtained from MDR-TB and DS-TB isolate cultures
- 66 Figure 2. Precipitation and spin-column CTAB DNA extraction method comparison
- 67 Figure 3. DNA shearing to 10 kb and 20 kb compared to 50 kb
- 68 Figure 4. Mean read depth and genome coverage when comparing each of the three kits
- 69 Figure 5. Comparison of BAM file read depth of *rpoB*
- 70 Figure 6. Drug resistance and lineage profile concordance resulting from phenotypic DSTs, ONT and
- 71 Illumina sequencing
- 72 Figure 7. The recommended ONT WGS TB pipeline, including culturing conditions, DNA extraction
- 73 methodology, optimal DNA input library preparation kit, basecalling and data analysis
- 74

75 Abstract

76 Background: Delays in accurate diagnosis of drug resistant tuberculosis (DR-TB) can hinder

treatment. Whole genome sequencing (WGS) provides more information than standard molecular

and phenotypic testing, but commonly used platforms are expensive to implement, and data
 interpretation requires significant expertise.

80

81 Aims: We aimed to optimise a TB WGS diagnostic pipeline balancing user-friendliness, cost-

82 effectiveness and time to results, whilst ensuring accuracy.

83

Materials and methods: Growth conditions, DNA extraction protocols and Oxford Nanopore Technologies (ONT) library preparation kits were compared. Software for basecalling and analysis were evaluated to find the most accurate resistance SNP and lineage predictor.

87

Results: Optimally, a spin-column CTAB DNA extraction method was combined with the RBK110.96 library preparation kit, high accuracy basecalling and data analysis using TB-Profiler. Compared with Ullumina, the pipeline was concordant for 16/17 (94%) isolates (lineage) and for 17/17 (100%) isolates (resistance SNPs). Our pipeline was 71% (12/17) concordant with phenotypic drug susceptibility test (DST) results. Time-to-diagnosis was around four weeks.

93

94 Conclusions: This optimised TB sequencing pipeline requires less time expertise to run and analyse
95 than Illumina, takes less time than phenotypic DSTs and the results are comparable with Illumina.
96 The cost per sample is comparable with other methods. These features make it an important tool for
97 incorporating into routine DR-TB diagnostic pipelines and larger scale drug resistance surveillance in
98 all settings.

99

100 Keywords: tuberculosis, drug resistance, whole genome sequencing, Oxford Nanopore, MinION,
 101 diagnosis

102

103 Abbreviations

СТАВ	Cethyl trimethyl ammonium bromide
CLI	Command line interface
CPU	Central processing unit
DR-TB	Drug resistant tuberculosis
DS-TB	Drug sensitive tuberculosis
DST	Drug sensitivity test
GPU	Graphics processing unit
GUI	Graphical user interface
НАС	High accuracy (basecalling)
LMIC	Low- and middle-income country
MDR	Multi-drug resistant
ONT	Oxford Nanopore Technologies
QC	Quality control
RoC	Republic of Congo
RR	Rifam picin-resistant
SD	Standard deviation
SUP	Super-high accuracy (basecalling)
ТВ	Tuberculosis
WGS	Whole genome sequencing
XDR	Extensively-drug resistant

104

105 Introduction

106

107 Treatment for drug-resistant tuberculosis (DR-TB) is intensive and can take up to 20 months to 108 complete, compliance can be low due to drug toxicity, and there is increased risk of mortality (1). 109 Misdiagnosis and delays to correct diagnosis, both between drug sensitive (DS-TB), DR-TB and multi-110 drug resistant (MDR-TB) strains, and the differentiation between M. tuberculosis and non-111 tuberculosis mycobacteria (NTMs), can complicate and delay appropriate treatment. Delayed 112 treatment is associated with high early mortality and the increase in drug resistance prevalence (2). 113 Whilst the prevalence of DR-TB has remained stable over the last decade, the top 30 countries with 114 the highest TB prevalence identified by WHO are low- and middle-income countries (LMICs) (3). DR-115 TB has been most commonly reported from Southern America and Central Asia, although data is not 116 available from many African countries (4,5). Phenotypic drug sensitivity testing (DST) tends to be 117 restricted to reference facilities or specialist centres, but the roll out of molecular assays such as the 118 GeneXpert MTB/RIF Ultra and MTB/XDR (Cepheid) or the line probe assay GenoType® MTBDR

(Bruker Corporation) has allowed more localised testing. However, these are incomprehensive
 targeted methods which are limited to detecting specific resistance-encoding mutations to certain
 drugs (6,7).

122

123 Whole genome sequencing (WGS) has emerged as a diagnostic tool for DR-TB cases (8–10). WGS is a comprehensive molecular diagnostic test that can identify mutations for all drugs in one assay 124 125 including novel drug resistance mutations and novel drug targets. It can predict resistance through 126 gene inactivation caused by multiple mutations, frameshift mutations or large structural variations in 127 the genome [9]. WGS can also identify TB lineages and mixed strain infections (11). In outbreak 128 situations, WGS is a powerful tool to identify transmission chains and clusters (12). In cases of 129 negative treatment outcomes, WGS can differentiate between cases of relapse, due to treatment 130 failure, and reinfection, which might be due to failure to develop protective immunity, through 131 calculating the genetic distance between pre- and post-treatment M. tuberculosis genomes (13). 132 Despite the increasing availability of sequencing platforms in LMICs, the lack of bioinformaticians, 133 data analysis training opportunities, and high-performance computing facilities have been a 134 bottleneck to the roll out of WGS globally (14).

135

Despite the potential of WGS, *M. tuberculosis* is a challenging organism to work with. DNA extraction is complicated by the complex cell wall structure (15). Many laboratories utilise the cethyl trimethyl ammonium bromide (CTAB) method (16), which generally produces a higher yield of genomic DNA of good integrity and purity for sequencing applications compared to commercial kits, and the reagents for which are mostly available and commonly used in TB laboratories in LMICs. DR-TB isolates tend to be slower to grow than DS-TB ones and generally produce less biomass, which can make extracting sufficient amounts of genomic DNA more difficult (17).

143

The mycobacterial genome has a high GC content (>60%) and multiple repeat regions. These structural features create challenges when considering sequencing library preparation and data analysis (18,19). On the other hand, an advantage in the analysis of the DR genotype for *M*. *tuberculosis* is that mycobacterial resistance is mainly dependent on the evolution of mutations such as single nucleotide polymorphisms (SNPs) and insertions or deletions (INDELs) within chromosomal genes rather than horizontal gene transmission (20).

150

The employment of short read, high throughput sequencing platforms, such as the Illumina MiSeq, is established for DR-TB genotyping (21–23), but these platforms have high resource requirements and highly skilled operators, and in consequence such large scale sequencing is not always available, especially in resource-constrained settings. In contrast, long read sequencing offered by ONT using the MinION; a small, portable device, is accessible to resource-constrained environments because of lower set-up costs and less complex training needs. Long read sequencing can additionally be advantageous for sequencing complex genomes which are GC rich or have many repeated regions.

158

There is little research from resource-constrained settings on the use of ONT platforms for TB diagnosis. Those publishing have often done so as individual research studies (24–29). Previous studies often made use of the ligation-based ONT library preparation (25,28). These require costly third-party reagents and high DNA input (1 µg), which can be hard to routinely obtain. If optimised appropriately, use of the rapid barcoding kits, employing multiplexing, should improve cost effectiveness (24).

165

Whilst phenotypic DSTs are the benchmark and used as a standard as there are international standards, diagnosis utilising WGS may help to provide more accurate results and therefore a faster correct drug regimen. Genomics is especially important in countries with no DST capabilities, or for new drugs like bedaquiline, where there is no other diagnostic. Currently, there does not appear to

170	be a TB sequencing protocol that could be integrated into diagnostic pipelines in resource
171	constrained settings to aid DR-TB diagnosis. We aimed to develop a pipeline, optimising
172	methodology to create a tool that had an optimal combination of accuracy, speed, cost-effectiveness
173	and user-friendliness.

174

175 Materials and methods

176

177 The full manual for this pipeline, including protocols and tutorial videos can be found on the

178 PANDORA-ID-NET Global Health Network hub (30).

179

180 *M. tuberculosis* samples and ethics statement

17 *M. tuberculosis* isolates from an archive maintained by the Centre for Clinical Microbiology (CCM) at University College London (UCL), which have metadata and phenotypic drug sensitivity data (streptomycin, isoniazid, rifampicin, ethambutol plus pyrazinamide) were utilised. Eight DS-TB isolates, five isoniazid mono-resistant isolates and four MDR-TB isolates were selected. The study did not include live participants. The study used archived *M. tuberculosis* isolates and no patient data was included in the study. There is no means to associate the isolates with the original source and ethical approval was not required.

188

189 Growth of *M. tuberculosis*

M. tuberculosis isolates were incubated in MGIT tubes (Becton Dickson), using the BD BACTEC[™]
 MGIT[™] automated mycobacterial detection system or on Middlebrook 7H11 slopes (EO laboratories)
 and incubated at 37°C in a static incubator. To identify the optimal growth time to achieve the
 greatest DNA yield, two representative MDR-TB and two DS-TB samples were selected from the
 collection. 500 µL of MGIT subcultures were seeded onto 7H11 slopes and into MGIT tubes and left

to grow. Once the MGIT flagged positive, each isolate was further cultured for 2, 3 or 4 weeks, after

- 196 which DNA was extracted.
- 197

198 DNA extraction

- 199 Two different CTAB methods were compared. For each extraction method, 400 µL of liquid culture
- 200 taken from a MGIT tube was used.

201

202 Method 1: The precipitation CTAB DNA extraction method, as described in Kent *et al.* (16) was 203 optimised, with the addition of a 15-minute sonication step after heat killing and 3 μL yeast tRNA 204 (Fisher Scientific) at the isopropanol precipitation step. DNA was eluted into 25 μL molecular grade 205 water.

206

207 Method 2: A spin-column CTAB method, developed by ONT, was compared. Briefly, samples were 208 heat killed, then glass beads and lysozyme (10mg/mL) added. The samples were incubated in a 209 shaking incubator at 37°C for 15 min at 800 RPM. Proteinase K and CTAB buffer were added and 210 then incubated at 56°C for 30 min at 1000 RPM. 5M NaCl was added and the debris pelleted by 211 centrifugation, before a modified version of the Monarch Genomic Purification Kit (New England 212 Biosciences) was followed. The full protocol for spin-column CTAB is in supplementary materials S1.

213

214 DNA quantification

DNA quantified using spectrophotometry and the Qubit[™] dsDNA BR Assay Kit (Thermo Fisher) and
 DNA size and integrity confirmed using electrophoresis with the Genomic DNA ScreenTape and
 reagents on the TapeStation 4150 (Agilent Technologies Inc.).

218

219 DNA shearing

DNA was sheared mechanically using g-TUBES (Covaris), following manufacturer's instructions (31). Samples with an average size of 10 kb, 20 kb and ~50 kb were sequenced for 2 hours each and the output number of reads, N50 (the sequence length of the shortest contig at 50% coverage of the total genome assembly) and bases compared.

224

225 Library preparation

DNA libraries were prepared using either the Rapid Barcoding Kit (SQK-RBK004) (ONT) with a DNA input of ~400 ng, the newer Rapid Barcoding Kit 96 (SQK-RBK110.96) (ONT) with a DNA input of between 50-200 ng, or the PCR Barcoding kit (SQK-RPB004) (ONT) with DNA inputs of 1-5 ng, following the respective ONT kit protocols (32–34). DNA libraries were prepared from the same spincolumn DNA extractions for Illumina sequencing using the DNA Prep, (M) Tagmentation (24 Samples, IPB) library preparation kit (Illumina) and the MiSeq Reagent Kit v3 (600-cycle) (Illumina) (35,36).

232

233 Sequencing and basecalling

Twelve or 24 barcoded samples were run together on a flow cell version R9.4.1 (ONT) using a MinION device for 72 hours, using the default parameters on the MinKNOW software (v23.04.6). Basecalling was performed either by the MinKNOW software alongside sequencing or using the Guppy basecalling software (v6.5.7) (ONT) (37), using either the flip-flop Fast, high accuracy (HAC), or super-high accuracy (SUP) algorithm. Basecalling was undertaken on a 32 GB RAM CPU computer (for specifications, see Supplementary materials S2).

240

241 Data analysis

Fastq files were quality checked (QC) using FastQC (v0.21.1) and MultiQC (v1.15) (38,39). Barcodes were demultiplexed and trimmed from the reads using Guppy. To view depth and coverage of the

244	sequences, fastq files were aligned to the H37Rv reference genome (NCBI Reference Sequence
245	NC_000962.3) using minimap2 (v2.26) (40), then sorted and indexed using SAMtools (v1.17) (41).
246	Alignments were visualised using Artemis (v18.1.0) (42). Depth and coverage were calculated using
247	SAMtools. Fastq files were input to the resistance gene SNP and lineage calling software configured
248	for ONT data, Mykrobe (v0.10.0) (43) and TB-Profiler (v4.4.0) (44) graphical user interfaces (GUIs) to
249	compare accuracy. ONT results were compared to Illumina data obtained from the same extraction.
250	Drug resistance SNPs with a confidence grading of \geq 3, as defined by the WHO were included in the
251	comparison (45). Data were analysed using Prism (v10.0.0.153) (GraphPad). Sequence data were
252	deposited under Project accession number PRJEB68143 on the European Nucleotide Archive and
253	outlined in supplementary materials S3.

254

255 Role of the funding source

The study sponsors had no role in the design, data collection, analysis or write up of this study. No funding (real or in kind) was received from ONT.

258

259 Results

260

DNA yield and fragment size for cultures sampled over time are displayed in Figure 1. The mean DNA yield for the MDR-TB isolates was 688 ng (SD=413) (from MGIT liquid culture) and 966 ng (SD=841) (from 7H11 slopes), whilst for the DS-TB isolates it was 1414 ng (SD=1265) (MGIT) and 1712 ng (SD=1327) (7H11). The quantity of DNA obtained from 7H11 was significantly higher than from MGITs especially for the MDR-TB isolates (*p*=<0.0001, unpaired t-test). For MDR-TB isolates, both the MGIT and 7H11 yields did not change significantly over time. For DS-TB isolates, for both the MGIT and 7H11 cultures, the yields decreased over time.

268

269 Figure 1. Genomic DNA yield and integrity obtained from MDR-TB and DS-TB isolate cultures. 270 Overall, 7H11 slopes produced the greatest yield of DNA, whilst MGIT tubes produced the greatest 271 DNA size. A) DNA yields extracted from MGIT tubes over time; there was no change in MDR-TB DNA 272 yield, but the DS-TB isolate yield decreased. B) DNA amounts extracted from 7H11 slopes over time; 273 there was no change in MDR-TB DNA yields, but DS-TB isolate yields decreased. C) Size of DNA 274 extracted from MGIT tubes over time; both MDR-TB and DS-TB isolates increased over time. D) Size 275 of DNA extracted from 7H11 slopes over time; the MDR-TB isolates peaked at week 3 and then decreased (p=0.0025), the DS-TB isolates peaked at weeks 3 and 4 (p=0.01). Significance was 276 277 calculated using One-Way ANOVA and Tukey's post ad hoc analysis.

278

279 The largest DNA fragments for both MDR-TB and DS-TB isolates was obtained from MGIT cultures. 280 The mean size for the MDR-TB isolates was 56,150 bp (Standard Deviation (SD)=6171) (MGIT) and 281 30,439 bp (SD=13,890) (7H11), whilst for the DS-TB isolates it was 54,776 bp (SD=5028) (MGIT) and 282 18,618 bp (SD=7134) (7H11). There were no significant differences between the means of DNA sizes 283 for isolates grown in MGITs or on 7H11 for either MDR-TB or DS-TB isolates. For the MDR-TB 284 isolates, when cultured in MGIT, the DNA size increased over time, whereas on 7H11, the DNA size 285 peaked at week 3 (p=0.01, one-way ANOVA). For the DS-TB isolates, the increased over time in both 286 the MGIT and 7H11 cultures.

287

288 DNA yield and DNA size results from the precipitation and spin-column CTAB extraction method 289 were compared for MGIT and 7H11 cultures and stratified into resistance categories (Figure 2).

290

Figure 2. Precipitation and spin-column CTAB DNA extraction method comparison. A) DNA yield measured using Qubit dsDNA broad spectrum kit, B) Size (bp) measured using the TapeStation genomic DNA kit. Apart from spin-column CTAB from MGIT tubes, all other methods provided the minimum required yield, although precipitation based CTAB protocols provided higher yields. Spin-

column CTAB from MGIT media also provided the smallest size. Significance was calculated using
One-Way ANOVA and Tukey's post ad hoc analysis.

297

298 We carried out MinION-based sequencing of selected samples. Firstly we looked at fragment size, as 299 in our experience, sequencing coverage can be reduced both by fragments that are too short and 300 too long. Long fragment lengths can especially inhibit read output for the mycobacteria. To do this 301 we generated shorter DNA fragments (20 and 10 kb average size) which we compared with the 302 original (50 kb) samples. A size of 20 kb resulted in the greatest number of reads, bases and N50 303 (Figure 3). The obtained N50 in sequencing was significantly higher with the 20 kb input DNA 304 fragments compared to the other two sizes (p=0.01, one-way ANOVA). Although there was variation 305 in the number of reads and bases obtained between the DNA sizes tested, the differences were not 306 significant (p>0.05, one-way ANOVA).

307

Figure 3. DNA shearing to 10 kb and 20 kb compared to 50 kb. A) number of reads (no significant
difference) B) N50 (overall *p*=0.01) and C) total number of bases (no significant difference). One-Way
ANOVA and Tukey's multiple comparison test was applied.

311

312 We compared different library preparation kits, all three of which are rapid, transposase-based kits. 313 SQK-RPB004 used a PCR amplification step resulting in fragments of around 4000 bp, the other two 314 were different versions of kits that utilise a transposase that cuts native DNA to add the sequencing 315 adapter, and has a major impact on fragment length. When 12 randomly selected isolates were 316 barcoded and multiplexed and sequenced on one flow cell, the PCR-based SQK-RPB004 kit gave a 317 greater mean read depth (mean=394x, SD=762) than the native kits, but the genome coverage was 318 low (mean=67%, SD=19). Whilst the coverage was improved using the older native DNA-based kit 319 (SQK-RBK004) (mean=80%, SD=38), the read depth was lower (mean=4x, SD=3). The newer native 320 DNA-based kit (SQK-RBK110.96) provided an improved depth for both precipitation DNA extraction

321	method (mean=13x, SD=9) and spin-column CTAB method (mean=49x, SD=36), and improved
322	genome coverage (mean=84.6%, SD=31 and 99.8%, SD=2 respectively). Figure 4 highlights the
323	quality scores for each of the kits. When 24 samples were run together, the mean depth was
324	reduced to 18x (SD=25).
325	
326	Figure 4. A) Mean read depth and B) genome coverage when comparing each of the three kits.
327	Statistical significance calculated using One-Way ANOVA and Tukey's multiple comparisons test.
328	pCTAB = precipitation CTAB, cCTAB = spin column CTAB. Numbers in brackets denote the number of
329	samples multiplexed per run.
330	
331	When the assembled BAM files were viewed for rpoB, where most rifampicin-resistance SNPS map
332	(as an example), the PCR-based SQK-RPB004 kit showed isolated, highly amplified regions and other
333	regions with no coverage (see Figure 5). Native library preparation kits demonstrated a better
334	coverage for the whole <i>rpoB</i> gene.
335	
336	Figure 5. Comparison of BAM file read depth of <i>rpoB</i> for A) the PCR-based SQK-RPB004 kit, showing
337	low coverage, B) SQK-RBK004 kit showing greater coverage and C) SQK-RBK110.96 resulted in the
338	best coverage and depth, using Artemis.
339	
340	Here we compared three different bioinformatic tools Fast basecalling was compared with high
341	accuracy (HAC) and super high accuracy (SUP) basecalling. The mean number of .fast5 input files was
342	6.4 (SD=1.5) (Table 1). Whilst SUP basecalling was the slowest, it did provide significantly better
343	quality (Q) scores.
344	

	Fast	НАС	SUP	One-way ANOVA significance
Mean time (minutes) (SD)	15 (5.9)	205 (65.4)	>36 hours	<i>p</i> =<0.0001

	Mean Q score (SD)	17.1 (0.2)	19.7 (0.3)	20.8 (0.3)	p=<0.0001	
	Mean accuracy (SD)	98.02% (0.06)	98.94% (0.05)	99.13% (0.05)	<i>p</i> =<0.0001	
345	Table 1. Comparison of	basecalling algorit	nms. One-way AN	OVA was used to	o test statistical	
346	significance. When Tukey's	multiple compariso	ons test was applied	d, there was a signi	ficant difference	
347	of <i>p</i> =<0 [,] 0001 between each	of the basecalling	algorithms for time	, mean Q score and	d accuracy.	
348						
349	The DNA samples came from strains with known DR phenotypes and genotypes. Fast, HAC and SUP-					
350	basecalled versions of each of the files were analysed using TB-Profiler to compare resistance SNP					
351	and lineage identification (Table 2). All isolate's median read depths were >40x. Compared with SUP					
352	basecalling, Fast basecalling agreed for 15/17 (88%) samples for lineage and all resistance SNPs. The					
353	sample for which Fast basecalling missed a SNP (streptomycin gidC 102de1G) had a depth of 47x.					
354	The sample for which Fast basecalling called lineage 3, and HAC and SUP called lineage 4.3, had a					
355	depth of 85x. HAC and SUP basecalling agreed for 17/17 (100%) samples. For the complete					
356	basecalling comparison dataset, see Supplementary materials S4.					

357

	Average	Fast vs SUP			HAC vs SUP		
	read depth	Lineage	Drug resistance	Total concordance	Lineage	Drug resistance	Total concordance
DS-TB	90	7/8 (88%)	8/8 (100%)	7/8 (88%)	8/8 (100%)	8/8 (100%)	8/8(100%)
Isoniazid mono	111	5/5 (100%)	4/5 (80%)	4/5 (80%)	5/5 (100%)	5/5 (100%)	5/5 (100%)
MDR-TB	72	4/4 (100%)	4/4 (100%)	4/4 (100%)	4/4 (100%)	4/4 (100%)	4/4 (100%)
Total isolates 85 16/17 (94%) 16/17 (94%) 15/17 (88%) 17/17 (100%) 17/17 (100%) 17/17 (100%)					17/17 (100%)		
358 Table 2. Concordance of different basecalling models, assuming greatest accuracy using SUP							
359 basecalling. HAC and SUP were 100% concordant, Fast basecalling called one lineage differently and							

360 missed one drug resistance SNP, compared to HAC and SUP basecalling. Isoniazid mono-resistance is361 defined by phenotypic DSTs.

362

363 Using phylogenetic DSTs as a guide, HAC-basecalled data were put through TB-Profiler and My	Mykrobe.
-------------------------------------------------------------------------------------------------	----------

364 Mykrobe called a mixed population of lineage 3 and 4.6.2.2 for the sample where Fast, HAC and SUP

disagreed in TB-Profiler (Table 3). The complete dataset can be found in Supplementary materials S5.

366

Mykrobe vs TB-Profiler	Lineage	Drug resistance	Total concordance
DS-TB	7/8 (88%)	7/8 (88%)	7/8 (88%)
Isoniazid mono-resistance	5/5(100%)	5/5 (100%)	5/5 (100%)
MDR-TB	4/4 (100%)	1/4 (25%)	1/4 (25%)
Total isolates	16/17 (94%)	13/17 (76%)	13/17 (76%)
	-	· · · · · · · · · · · · · · · · · · ·	· · · · ·

367 Table 3. Summary comparison of the TB sequencing data analysis software Mykrobe, as compared

369

370 HAC-basecalled consensus sequence fastg files were compared with the equivalent Illumina fastg 371 files for each isolate, to identify lineage and resistance SNP concordance using TB-Profiler. ONT data 372 was concordant with phenotypic DSTs in 12/17 (71%) samples, taking into account phenotypic DST 373 testing only included rifampicin, isoniazid, ethambutol and streptomycin, and pyrazinamide for MDR 374 samples. ONT picked up SNPs in one DS-TB sample, one isoniazid mono-resistant samples two MDR-375 TB samples which phenotypic DSTs concluded were sensitive. Both ONT and Illumina showed two 376 phenotypically pyrazinamide-resistant isolates as sensitive. The full list of phenotypic and genotypic 377 drug resistances found, including full SNP calls are in Supplementary materials S6. 378 379 The ONT pipeline was overall 94% (16/17) concordant (16/17 for lineage and 17/17 for all resistance 380 SNPs) with Illumina data. For lineage, one DS-TB sample appeared to be a mixed population of 381 lineage 3 (the only one picked up by Illumina) and 4.6 (picked up by HAC and SUP-basecalling in the 382 ONT pipeline. but not Fast). An overview of these results is in Figure 6. 383 384 Figure 6. Drug resistance and lineage profile concordance resulting from phenotypic DSTs, ONT and

385 Illumina sequencing. P = phenotypic DST results, O = Oxford Nanopore results, I = Illumina results, M

386 = mixed (lineage 3 and 4), S = sensitive, R = resistant, NT = not tested.

³⁶⁸ against TB-Profiler.

387

388 Table 4 outlines each component analysed, which tested component performed the best for each

389 category, and the overall recommended pipeline options.

390

Step	Culturing (media)	Culturing (length of time)	DNA extraction	Library preparation	Basecalling algorithm	Analysis software
Reasoning for testing	Cost, DNA quality and quantity	Optimal DNA yield	Optimisation of DNA quality and quantity (reduce inhibitors)	Input DNA vs output data	Accuracy vs speed (dependent on computing power)	Accuracy and detail vs ease of use
Comparators	MGIT, 7H11	2 weeks, 3 weeks and 4 weeks post- MGIT flagging	Precipitation CTAB, Spin-column CTAB	RPB004 (PCR), RBK004 (native), RBK110.96 (native)	Fast, HAC and SUP	TB-Profiler, Mykrobe
Cheapest	7H11	n/a	Precipitation CTAB	RBK110.96	n/a	n/a
Fastest	n/a	2 weeks post-MGIT flagging	Spin-column CTAB	RBK004	Fast	Computing power/server speed dependent
Most accurate	n/a	2 or 3 weeks post- MGIT flagging	n/a	RBK110.96	HAC or SUP	TB-Profiler
Most user- friendly	7H11 (if bought ready made)	n/a	Both protocols are similar	RBK004	n/a	GUIs are user friendly
Recommended option	7H11	2 weeks post-MGIT flagging	Spin-column CTAB	RBK110.96	HAC	TB-Profiler GU

Table 4. Table of pipeline steps and overall recommended choice for each section of the pipeline.

392

393 Discussion

394

395 We conclude that a WGS pipeline using ONT technology is feasible for the identification of SNPs that

396 determine *M. tuberculosis* drug resistance and lineage and is suitable for our aim to create a

397 pragmatic pipeline for use in LMICs. Taking into consideration the data presented here, we propose

the following pipeline (Figure 7) as the optimized route for TB WGS.

399

400 Figure 7. The recommended ONT WGS TB pipeline, including culturing conditions, DNA extraction

401 methodology, optimal DNA input library preparation kit, basecalling and data analysis. Images taken

402 from Windows 10 Education and ShutterStock.

4	n	З
-	v	-

In our study, the ONT pipeline showed the same accuracy as Illumina but showed less concordance with phenotypic DSTs. This is likely due to the complex relationship between genotypic and phenotypic resistance. All phenotypic and genotypic discordances in this study were seen in three drugs; streptomycin, ethambutol and pyrazinamide, each of which are known to have multifaceted resistance mechanisms, which are not fully understood, thus further work is needed (46).

409

We identified isolates with phenotypic sensitivity and genotypic resistance, which may be a result of subpopulations and heteroresistance, which is a growing concern. When phenotypic resistance and genotypic sensitivity was seen, this may have been a result of the specific resistance SNPs causing genotypic resistance not being included in the analysis software databases. Ultimately, the standard will be which drugs are clinically relevant, and whilst phenotypic DSTs are the current benchmark, with the accumulation of genotypic resistance knowledge, this may shift to a molecular benchmark in the future.

417

Whilst a reduced fragment size did improve sequencing read yield, the Covaris g-TUBEs added a significant cost to the pipeline. We found that extracting from 7H11 plates in conjunction with spincolumn CTAB DNA extraction, produced a fragment length of <30 kb. Thus, we recommend that g-TUBEs could be used as an optional extra within the pipeline, if different media and extraction methodologies are utilised.

423

424 Whilst the precipitation CTAB method does provide adequate DNA size and yield for use with the 425 new native ONT library preparation kit (SQK-RBK110.96), lower numbers of reads and bases were 426 generally achieved compared with spin-column CTAB extraction, although the latter produces lower 427 DNA yields. We hypothesise that the co-precipitation of inhibitors, possibly from the mycobacterial

428 cell wall, may be interfering with the binding of the transposase complex used in native library
429 preparation kits, so that less DNA is adapted and therefore is unable to be sequenced.

430

The cost of WGS has decreased greatly in the last few years, making it more accessible for resource constrained settings. Whilst the cost per sample may be lower using Illumina due to the higher throughput, if the samples have to be sent away due to a lack of local facilities, extra costs are likely to be incurred. If batching is used to reduce costs, then this can increase the time to results in smaller laboratories with fewer samples. Costs in this pipeline could be reduced by substituting products or equipment, although automated systems and high-speed computers may be beneficial in the long term.

438

439 The bottleneck of this pipeline is likely to be basecalling, unless high-computing power set ups are 440 available. The time from culture to drug resistance and lineage results could be within four weeks if 441 the appropriate human resources and computers are available, with 2-3 weeks of culturing and a 442 week for extraction, quantification, sequencing and analysis. Whilst this is not as fast as other 443 methods such as GeneXpert or line probe assays which are commonly available in local regional 444 laboratories, it is comparable with phenotypic DSTs. In terms of the ease-of-use of this pipeline, if 445 users opt to use Guppy within the MinKNOW GUI, minimal CLI knowledge is required, meaning less 446 training would be required for routine laboratory staff, and should therefore be faster to implement 447 and more widely usable.

448

Some complications were encountered in this study, and in sequencing of the mycobacteria in general. This pipeline requires cultured isolates, and thus the use of a biosafety level 3 (BSL3) laboratory, which are not widely available. The possibility of utilising another site's BSL3 facilities to grow cultures, heat killing and then transferring samples to the sequencing laboratory is an alternative route but may increase the time to results.

454

With a greater understanding of genomic drug resistances, plus ever-evolving bioinformatics software, the accuracy TB diagnostics will improve. To increase the speed of time to results, sequencing direct from sputum would cut out culturing time, but is yet to be standard practice in routine diagnostics. Targeted kits, such as the Illumina and GenoScreen Deeplex[®] Myc-TB Combo Kit are an alternative to WGS but provide less information (47). An ONT targeted kit for DR-TB has recently been approved by the WHO (48).

461

462 Whilst the necessity of culture in this pipeline does mean time to results is in weeks not minutes or 463 days, the resolution of resistance and lineage detail obtained from ONT WGS sequencing is greater 464 than that obtained from standard diagnostic tests such as GeneXpert, line probe assays or 465 phenotypic DSTs, and is comparable to Illumina sequencing. There is a need for genotypic drug 466 resistance data, not only for routine diagnostics, but also for geographical drug resistance profiling 467 and surveillance to aid correct prescribing, and it is important that data is collected as broadly as 468 possible (9). The ability of smaller, localised laboratories to participate in this is vital and the 469 optimised ONT pipeline presented here will help to facilitate WGS roll out within these sites.

470

471 Conflict of interest

This project obtained technical support from Oxford Nanopore Technologies Ltd (ONT), but ONT did
not contribute financially to the study.

474

475 Data sharing statement

All genetic fasta data obtained in this study is available under the Project accession number
PRJEB68143 on the European Nucleotide Archive upon publication. The full manual, including
further information and tutorial videos, relating to this protocol is available on the PANDORA-ID-NET

- 479 Global Health Network hub pages: https://pandora.tghn.org/sequencing/tuberculosis-sequencing-
- 480 pipeline/. All data and additional material is Open Access.

481

482 References

- 483 1. Thwaites G, Nguyen N V. Linezolid for Drug-Resistant Tuberculosis. New England Journal of
- 484 Medicine. 2022 Sep 1;387(9):842–3.
- 485 2. Adamu AL, Gadanya MA, Abubakar IS, Jibo AM, Bello MM, Gajida AU, et al. High mortality
- 486 among tuberculosis patients on treatment in Nigeria: A retrospective cohort study. BMC
- 487 Infect Dis. 2017 Feb 23;17(1).
- 488 3. World Health Organization. Global Tuberculosis Report. 2019.
- 489 4. World Health Organization. Global Tuberculosis Report. 2016.
- 490 5. World Health Organization. Global Tuberculosis report. 2021.
- 491 6. Hain Lifescience GmbH. GenoType MTBDRsl VER 1.0 and VER 2.0 Your Important Assistance
- 492 for Detetion of XDR-TB [Internet]. [cited 2022 Sep 26]. Available from: https://www.hain-
- 493 lifescience.de/en/products/microbiology/mycobacteria/tuberculosis/genotype-mtbdrsl.html

494 7. Hain Lifescience GmbH. GenoType MTBDRplus VER 2.0 - Your Test System for a Fast and

- 495 Reliable Way to detect MDR-TB [Internet]. [cited 2022 Sep 26]. Available from:
- 496 https://www.hain-
- 497 lifescience.de/en/products/microbiology/mycobacteria/tuberculosis/genotype-
- 498 mtbdrplus.html
- 499 8. Satta G, Atzeni A, Mchugh TD. Mycobacterium tuberculosis and whole genome sequencing: a
- 500 practical guide and online tools available for the clinical microbiologist. Clinical Microbiology
- 501 and Infection [Internet]. 2017;23(2):69–72. Available from:
- 502 http://dx.doi.org/10.1016/j.cmi.2016.09.005
- 503 9. Mahomed S, Naidoo K, Dookie N, Padayatchi N. Whole genome sequencing for the
- 504 management of drug-resistant TB in low income high TB burden settings: Challenges and

- 505 implications. Tuberculosis [Internet]. 2017;107:137–43. Available from:
- 506 https://doi.org/10.1016/j.tube.2017.09.005
- 507 10. Takiff HE, Feo O. Clinical value of whole-genome sequencing of Mycobacterium tuberculosis.
- 508 Lancet Infect Dis [Internet]. 2015;15(9):1077–90. Available from:
- 509 http://dx.doi.org/10.1016/S1473-3099(15)00071-7
- 510 11. Sobkowiak B, Glynn JR, Houben RMGJ, Mallard K, Phelan JE, Guerra-Assunção JA, et al.
- 511 Identifying mixed Mycobacterium tuberculosis infections from whole genome sequence data.
- 512 BMC Genomics. 2018;19(1):1–15.
- 513 12. Nikolayevskyy V, Kranzer K, Niemann S, Drobniewski F. Whole genome sequencing of
- 514 Mycobacterium tuberculosis for detection of recent transmission and tracing outbreaks: A
- 515 systematic review. Tuberculosis. 2016;98:77–85.
- 516 13. Witney AA, Bateson ALE, Jindani A, Phillips PPJ, Coleman D, Stoker NG, et al. Use of whole-
- 517 genome sequencing to distinguish relapse from reinfection in a completed tuberculosis
- 518 clinical trial. BMC Med. 2017 Mar 29;15(1).
- 519 14. Satta G, Lipman M, Smith GP, Arnold C, Kon OM, McHugh TD. Mycobacterium tuberculosis
- 520 and whole-genome sequencing: how close are we to unleashing its full potential? Clinical
- 521 Microbiology and Infection [Internet]. 2018;24(6):604–9. Available from:
- 522 https://doi.org/10.1016/j.cmi.2017.10.030
- 523 15. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium
 524 tuberculosis. Tuberculosis. 2003;83:91–7.
- 525 16. Kent L, Hugh TDMC, Billington O, Dale JW. Demonstration of Homology between IS6110 of
- 526 Mycobacterium tuberculosis and DNAs of Other Mycobacterium spp. J Clin Microbiol.
- 527 1995;33(9):2290–3.
- 528 17. Levin BR, Lipsitch M, Perrot V, Schrag S, Antia R, Simonsen L, et al. The Population Genetics of
- 529 Antibiotic Resistance A Model of the Population Genetics of Antibiotic Resistance in the
- 530 Commensal Flora. Clinical Infectious Diseases. 1997;24(1):9–16.

- 531 18. Modlin SJ, Robinhold C, Morrissey C, Mitchell SN, Sarah M. Exact mapping of Illumina blind
- 532 spots in the Mycobacterium tuberculosis genome reveals platform-wide and workflow-
- 533 specific biases. 2020;
- Assal N, Lin M. PCR procedures to amplify GC-rich DNA sequences of Mycobacterium bovis. J
 Microbiol Methods. 2020;181:1–8.
- 536 20. Papaventsis D, Casali N, Kontsevaya I, Drobniewski F, Cirillo DM, Nikolayevskyy V. Whole
- 537 genome sequencing of Mycobacterium tuberculosis for detection of drug resistance: a
- 538 systematic review. Vol. 23, Clinical Microbiology and Infection. Elsevier B.V.; 2017. p. 61–8.
- 539 21. Pankhurst LJ, del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, et al. Rapid,
- 540 comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: A
- 541 prospective study. Lancet Respir Med. 2016;4(1):49–58.
- 542 22. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and
- 543 targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and
- 544 MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med. 2019;16(4):1–13.
- 545 23. The CRyPTIC Consortium. Genome-wide association studies of global Mycobacterium
- 546 tuberculosis resistance to 13 antimicrobials in 10,228 genomes identify new resistance
- 547 mechanisms. PLoS Biol. 2022;1–27.
- 548 24. Cervantes J, Yokobori N, Hong BY. Genetic identification and drug-resistance characterization
 549 of mycobacterium tuberculosis using a portable sequencing device. A pilot study. Antibiotics.
- 550 2020;9(9):1–15.
- 551 25. Bainomugisa A, Duarte T, Lavu E, Pandey S, Coulter C, Marais BJ, et al. A complete high-
- quality MinION nanopore assembly of an extensively drug-resistant Mycobacterium
- 553 tuberculosis Beijing lineage strain identifies novel variation in repetitive PE/PPE gene regions.
- 554 Microb Genom. 2018;4(7).


- 555 26. Bates M, Polepole P, Kapata N, Loose M, O'Grady J. Application of highly portable MinION
- 556 nanopore sequencing technology for the monitoring of nosocomial tuberculosis infection. Int
- 557 J Mycobacteriol. 2016;5:S24.
- 558 27. Yu G, Shen Y, Zhong F, Zhou L, Chen G, Fang L, et al. Diagnostic accuracy of nanopore
- 559 sequencing using respiratory specimens in the diagnosis of pulmonary tuberculosis.
- 560 International Journal of Infectious Diseases. 2022;0–33.
- 561 28. Smith C, Halse TA, Shea J, Modestil H, Fowler RC, Musser KA, et al. Assessing Nanopore
- 562 Sequencing for Clinical Diagnostics: a comparison of Next-Generation Sequencing (NGS) for
- 563 Mycobacterium tuberculosis. J Clin Microbiol. 2021;59(1):1–14.
- 564 29. Foster D, Coles S, Wyllie D, Robinson E, Ahyow L, Cox S, et al. Mycobacterium tuberculosis
- 565 whole-genome sequencing and cluster investigation handbook [Internet]. 2022 [cited 2022
- 566 Oct 4]. Available from: https://www.gov.uk/government/publications/tb-strain-typing-and-
- 567 cluster-investigation-handbook/mycobacterium-tuberculosis-whole-genome-sequencing-
- 568 and-cluster-investigation-handbook
- 569 30. Elton L, Stoker N, Rofael S. Tuberculosis whole genome sequencing diagnostics pipeline (using
- 570 Oxford Nanopore Technologies) v2.0. 2023.
- 571 31. Covaris. USER MANUALI : g-TUBE covaris. 2016;(10):1–9.
- 572 32. Oxford Nanopore Technologies. Rapid Barcoding kit protocol (SQK-RBK004). 2019. p. 1–4.
- 573 33. Oxford Nanopore Technologies. Rapid sequencing gDNA barcoding (SQK-RBK110.96)
- 574 [Internet]. 2022 [cited 2022 Dec 12]. Available from:
- 575 https://community.nanoporetech.com/docs/prepare/library_prep_protocols/rapid-
- 576 barcoding-kit-96-sqk-rbk110-96/v/rbk_9126_v110_revm_24mar2021
- 577 34. Oxford Nanopore Technologies. Rapid PCR Barcoding Kit (SQK-RPB004) protocol [Internet].
- 578 2020 [cited 2021 Jun 28]. p. 1–4. Available from:
- 579 https://community.nanoporetech.com/protocols/rapid-pcr-barcoding/checklist_example.pdf


- 580 35. Illumina. Illumina DNA Prep Reference Guide [Internet]. 2020. Available from:
- 581 www.illumina.com/company/legal.html.
- 582 36. Illumina. MiSeq [®] Reagent Kit v3 Reagent Preparation Guide FOR RESEARCH USE ONLY
- 583 Revision History 3 MiSeq Reagent Kits 4 Kit Contents and Storage Requirements 5 Flow Cell
- 584 Overview 6 Reagent Cartridge Overview 7 Prepare Reagents 9 Next Steps 12 Technical
- 585 Assistance. 2013.
- 586 37. Wick RR, Judd LM, Holt KE. Performance of neural network basecalling tools for Oxford
- 587 Nanopore sequencing. Genome Biol. 2019;20(1):1–10.
- 588 38. Babraham Bioinformatics. FastQC [Internet]. 2019 [cited 2021 Jun 28]. Available from:
- 589 https://www.bioinformatics.babraham.ac.uk/projects/fastqc/
- 590 39. Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: Summarize analysis results for multiple
- tools and samples in a single report. Bioinformatics. 2016;32(19):3047–8.
- 592 40. Li H. Minimap2: Pairwise alignment for nucleotide sequences. Bioinformatics.
- 593 2018;34(18):3094–100.
- 594 41. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence
- 595 Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078–9.
- 596 42. Carver T, Harris SR, Berriman M, Parkhill J, McQuillan JA. Artemis: An integrated platform for
- 597 visualization and analysis of high-throughput sequence-based experimental data.
- 598 Bioinformatics. 2012;28(4):464–9.
- 599 43. Hunt M, Bradley P, Lapierre SG, Heys S, Thomsit M, Hall MB, et al. Antibiotic resistance
- 600 prediction for Mycobacterium tuberculosis from genome sequence data with mykrobe.
- 601 Wellcome Open Res. 2019;4.
- 602 44. Phelan JE, O'Sullivan DM, Machado D, Ramos J, Oppong YEA, Campino S, et al. Integrating
- 603 informatics tools and portable sequencing technology for rapid detection of resistance to
- anti-tuberculous drugs. Genome Med. 2019;11(1):1–7.

- 45. World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex
- and their association with drug resistance [Internet]. 2021. Available from:
- 607 https://www.who.int/publications/i/item/9789240028173
- 608 46. Khawbung JL, Nath D, Chakraborty S. Drug resistant Tuberculosis: A review. Vol. 74,
- 609 Comparative Immunology, Microbiology and Infectious Diseases. Elsevier Ltd; 2021.
- 610 47. Illumina. Illumina and GenoScreen Deeplex[®] Myc-TB Combo Kit [Internet]. [cited 2023 May
- 611 11]. Available from: https://emea.illumina.com/products/by-type/sequencing-kits/library-
- 612 prep-kits/deeplex-myctb-combo-kit.html
- 48. World Health Organization. Use of targeted next-generation sequencing to detect drug-
- 614 resistant tuberculosis [Internet]. 2023 [cited 2023 Sep 1]. 1–8 p. Available from:
- 615 https://apps.who.int/iris/rest/bitstreams/1521320/retrieve


616


617






А







													D	S-TB														
		S1			S2			S 3			S	4				S5				S6			S7				S8	
Lineage	-	2	2	-	4	4	-	4	4		Ν	N	М	-		4	4		-	2	2	-	4	4		-	1	1
Rifampicin	S	S	S	S	S	S	S	S	S	5	9	S	S	S		S	S		5	S	S	S	S	S	Í	S	S	S
Isoniazid	S	S	S	S	S	S	S	S	S	9	9	S	S	S		S	S		5	S	S	S	S	S		S	S	S
Ethambutol	S	S	S	S	S	S	S	S	S	9	9	S	S	S		S	S		5	S	S	S	S	S		S	S	S
Streptomycin	S	S	S	S	R	R	S	S	S	9	9	S	S	S		S	S		5	S	S	S	S	S		S	S	S
Moxifloxacin	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S		TΙ	S	S
Ofloxaxin	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S		TΙ	S	S
Amikacin	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S		T	S	S
Capreomycin	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S		TΙ	S	S
Kanamycin	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S		TΙ	S	S
Pyrazinamide	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S		T۱	S	S
Ethionamide	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S		TΙ	S	S
Ciprofloxacin	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S		T	S	S
Fluoroquinolones	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S		T	S	S
PAS	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S	I	TΙ	S	S
Cycloserine	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N ⁻	-	S	S	N	Т	S	S	NT	S	S		ΝT	S	S
Delaminid	NT	S	S	NT	S	S	NT	S	S	N	T S	S	S	N	-	S	S	N	Т	S	S	NT	S	S		١T	S	S
	Ч	0	_	۵.	0	_	٩	0	_	6		D	_	٩		0	_	1	r	0	_	۵.	0	_		Ч	0	_

٩.

ο

_

۵.

0

_

0

_

۵

	I soni azid mono-resistance																				
	1			12			13			14			15			M1					
Lineage	-	4	4		-	4	4		-	4	4	-	4	4	-	4	4	-	4	4	
Rifampicin	S	S	S		S	S	S		S	S	S	S	S	S	S	S	S	R	R	R	
Isoniazid	R	R	R		R	R	R		R	R	R	R	R	R	R	R	R	R	R	R	
Ethambuto	S	S	S		S	S	S		S	S	S	S	S	S	S	S	S	S	R	R	
Streptomycin	S	S	S		S	R	R		S	S	S	S	S	S	S	S	S	R	R	R	
Moxifloxacin	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	NT	S	S	
Ofloxaxin	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	NT	S	S	
Amikacin	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	NT	S	S	1
Capreomycin	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	NT	S	S	1
Kanamycin	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	NT	S	S	
Pyrazinamide	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	R	R	R	
Ethionamide	NT	R	R		NT	R	R		NT	R	R	NT	R	R	N	R	R	NT	S	S	
Ciprofloxacin	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	NT	S	S	
Fluoroquinolones	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	NT	S	S	
PAS	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	NT	S	S	
Cycloserine	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	NT	S	S	
Delaminid	NT	S	S		NT	S	S		NT	S	S	NT	S	S	N	S	S	NT	S	S	I

٩.

ο

_

۵

ο

_

۵.

ο

_

۵.

ο

_

	-				•								
MDR-TB													
	М2				М3		M4						
-	2	2		-	2	2		-	4				
R	R	R		R	R	R		R	R				
R	R	R		R	R	R		R	R				
S	R	R		S	R	R		S	S				
R	S	S		S	S	S		R	R				
NT	S	S		NT	S	S		NT	S				
NT	S	S		NT	S	S		NT	S				
NT	S	S		NT	S	S		NT	S				
NT	S	S		NT	S	S		NT	S				
NT	R	R		NT	R	R		NT	S				
R	S	S		R	S	S		S	S				
NT	R	R		NT	R	R		NT	R				
NT	S	S		NT	S	S		NT	S				
NT	S	S		NT	S	S		NT	S				
NT	S	S		NT	S	S		NT	S				
NT	S	S		NT	S	S		NT	S				
NT	S	S		NT	S	S		NT	S				
	R S NT NT NT NT NT NT NT NT NT	- 2 R R R S NT S	N2 2 2 2 R R R R R R S R R R S R NT S S NT S S	N2 2 2 2 R R R R R R S R R R S S R S S NT S S	N2 2 2 2 R R R R R R S R S R S R NT S S S NT S NT R NT R NT S S S NT R NT S S S NT S S S NT S NT	N2 C C 2 2 - 2 R R R R R R R R S R R S R S S S R S S S R S S S NT S S NT S S NT S NT S S NT S S NT S NT S S NT R R NT S NT S S NT R S S NT R R NT S NT S S NT R R NT S NT S S NT NT S S NT NT S	N2 C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C	N2 C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C	N22222-2RRRRRRRRRRRRSRSSRSSSRSSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTRNTRRNTSSNTSSNTSSNTSSNTSNTSSNTSNTNTSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSSNTSS				

۵.

ο

_

۵

ο

	medRxiv preprint doi: https://doi.org/10.1101/2024.04.15.24305720; this version posted April 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .
4	s ve has NC
4 R S S S S S S S R S S S S S S S S S S S S S	rsio grai ND
R	n p nteo 4.0
S	osto d m
ĸ	ed / ledf
s c	Apr Rxiv
 S S	ii 1: / a ona
s	5, 2 lice l lic
 S	024 nse
S	ет. т
R	he dis
S	pla
S	y th
S	ght ie p
S	hol
S	der
-	for this preprint t in perpetuity.

